High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - Dose-response and schedule dependence

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2378-2384

  Patel, Shreyaskumar R ^a   Vadhan Raj, Saroj ^a   Papadopolous, Nicholas ^a   Plager, Carl ^a   Burgess, M Andrew ^a   Hays, Carolyn ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; OSTEOSARCOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030912403     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2378     Document Type: Article

References (16)

1. Bramwell V, Mouridsen H, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311-321, 1987
2. Amman KH, Ryan L, Elias A, et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126-131, 1989
3. Elias A, Eder J, Shea T, et al: High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 8:170-178, 1990
4. Benjamin RS, Legha SS, Patel SR, et al: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The M.D. Anderson experience. Cancer Chemother Pharmacol 31:5174-179, 1993 (suppl 2)
5. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1-10, 1989
6. Antman K, Crowley J, Balcerzak S, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
7. Edmonson J, Ryan L, Blum R, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxoroubicin and cisplatin against soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
8. Patel S, Vadhan-Raj S, Burgess M, et al: Dose-intensive chemotherapy in soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 15:522, 1996 (abstr 1681)
9. Schutte J, Kellner R, Seeber S: Ifosfamide in the treatment of soft tissue sarcomas: Experience at the West German Tumor Center, Essen. Cancer Chemother Pharmacol 31:5194-8198, 1993
10. LeCesne A, Antoine E, Spielmann M, et al: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfam7 ide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608, 1995
11. Chawla S, Rosen G, Lowenbraun S, et al: High dose ifosfamide (HDI) therapy in metastatic soft tissue sarcoma (STS). Proc Am Assoc Cancer Res 31:198, 1990 (abstr)
12. Chawla S, Rosen G, Lowenbraun S, et al: Role of high dose ifosphamide (HDI) in recurrent osteosarcoma. Proc Am Soc Clin Oncol 9:310, 1990 (abstr)
13. Vadhan-Raj S, Broxmeyer H, Hittelman W, et al: Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. J Clin Oncol 10:1266-1277, 1992
14. Lauterburg B, Nguyen T, Hartmann B, et al: Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 35:132-136, 1994
15. Quezado A, Wilson W, Cunnion R, et al: High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 118:31-36, 1993
16. Patel S, Forman A, Benjamin R: High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst 86:305-306, 1994